THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Therapeutic Solutions International, Inc.

Equities

TSOI

US8833781011

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets 12:21:00 2024-04-30 pm EDT			5-day change	1st Jan Change
0.000501 ^USD	-16.50%		-16.67%	-50.00%

Apr. 17	Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 04	Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients	CI

Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

March 04, 2024 at 09:00 am EST

Therapeutic Solutions International, Inc. (TSOI) announced the granting of a patent covering the ability of QuadraMune and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers.

Latest news about Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 17	CI
Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients	Mar. 04	CI
Therapeutic Solutions International, Inc. Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease	Dec. 11	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene	23-10-20	CI
Res Nova Bio Appoints George Delgado to Scientific Advisory Board	23-10-17	CI
Therapeutic Solutions International, Inc. Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils	23-09-29	CI
Therapeutic Solutions International Appoints Navneet Boddu to Scientific Advisory Board	23-09-18	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Therapeutic Solutions International, Inc. Announces FlorStilbene?? Demonstrates Synergy with Conventional Chemotherapy and Immunotherapy in Reducing Triple Negative Breast Cancer	23-08-21	CI
Allogen Biologics Inc. Successfully Manufactures JadiCell	23-08-16	CI
Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene?	23-07-18	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy	23-04-20	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Therapeutic Solutions International, Inc. Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Therapeutic Solutions International Advances Chronic Obstructive Pulmonary Disease Program by Identifying Novel B Regulatory Cell Mechanism of Action for Jadicell Universal Donor Adult Stem Cell	23-03-13	CI
Therapeutic Solutions International Announces Plans to Initiate Breast Cancer Clinical Trial Using Florstilbene Immune Stimulator Through Res Nova Bio Subsidiary	23-03-06	CI
Therapeutic Solutions International Launches Veltmeyer Institute for Advanced Biologics	23-02-21	CI
Therapeutic Solutions International Announces Improvements in Autism, Amyotrophic Lateral Sclerosis and Schizophrenia Cases Treated by Veltmeyer Institute for Advanced Therapeutics	22-12-05	CI
Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease	22-11-14	CI
Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc	22-10-27	CI
Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient	22-10-24	CI
Therapeutic Solutions International Identifies Cd103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for Jadicell Mesenchymal Stem Cell Mediated Lung Protection	22-10-03	CI

Chart Therapeutic Solutions International, Inc.

Duration

Period

Chart Therapeutic Solutions International, Inc.

More charts

Company Profile

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. It has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. It has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Medical Devices & Implants

	1st Jan change	Capi.
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.	-50.00%	2.64M
STRYKER CORPORATION	+12.85%	129B
SMITH & NEPHEW PLC	-9.23%	10.77B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+2.17%	9.05B
INSPIRE MEDICAL SYSTEMS, INC.	+19.97%	7.38B
GLAUKOS CORPORATION	+21.32%	4.88B
AXONICS, INC.	+7.12%	3.41B
ENOVIS CORPORATION	-0.50%	3.07B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-5.07%	2.24B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-4.22%	2.12B

Medical Devices & Implants